United Services Automobile Association Purchases 1,020 Shares of The Medicines Company (MDCO)

United Services Automobile Association raised its position in shares of The Medicines Company (NASDAQ:MDCO) by 0.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 392,724 shares of the company’s stock after purchasing an additional 1,020 shares during the quarter. United Services Automobile Association owned 0.53% of The Medicines worth $7,517,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC grew its stake in shares of The Medicines by 1.2% during the 3rd quarter. FMR LLC now owns 11,068,729 shares of the company’s stock valued at $331,066,000 after acquiring an additional 127,139 shares during the period. Vanguard Group Inc. grew its stake in shares of The Medicines by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 6,681,573 shares of the company’s stock valued at $199,846,000 after acquiring an additional 162,702 shares during the period. Vanguard Group Inc grew its stake in shares of The Medicines by 2.5% during the 3rd quarter. Vanguard Group Inc now owns 6,681,573 shares of the company’s stock valued at $199,846,000 after acquiring an additional 162,702 shares during the period. Westfield Capital Management Co. LP grew its stake in shares of The Medicines by 21.6% during the 4th quarter. Westfield Capital Management Co. LP now owns 4,604,719 shares of the company’s stock valued at $88,134,000 after acquiring an additional 817,508 shares during the period. Finally, Iridian Asset Management LLC CT grew its stake in shares of The Medicines by 75.4% during the 4th quarter. Iridian Asset Management LLC CT now owns 3,296,816 shares of the company’s stock valued at $63,101,000 after acquiring an additional 1,417,229 shares during the period.

Shares of NASDAQ:MDCO opened at $27.13 on Friday. The company has a quick ratio of 5.03, a current ratio of 5.05 and a debt-to-equity ratio of 31.23. The Medicines Company has a 12-month low of $16.69 and a 12-month high of $41.57. The company has a market cap of $2.00 billion, a P/E ratio of -9.32 and a beta of 1.29.

The Medicines (NASDAQ:MDCO) last posted its quarterly earnings results on Wednesday, February 27th. The company reported ($0.62) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.05). The Medicines had a negative return on equity of 2,119.03% and a negative net margin of 668.93%. During the same period in the previous year, the firm earned ($0.61) earnings per share. On average, sell-side analysts expect that The Medicines Company will post -1.64 earnings per share for the current year.

In other The Medicines news, Director Alexander J. Denner purchased 248,100 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average cost of $24.91 per share, with a total value of $6,180,171.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Alexander J. Denner purchased 325,000 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was acquired at an average cost of $25.45 per share, for a total transaction of $8,271,250.00. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 856,389 shares of company stock worth $20,246,298. 10.29% of the stock is owned by insiders.

A number of research analysts recently issued reports on MDCO shares. Zacks Investment Research downgraded The Medicines from a “hold” rating to a “sell” rating in a research note on Wednesday, November 21st. BidaskClub upgraded The Medicines from a “buy” rating to a “strong-buy” rating in a research note on Friday. Wolfe Research started coverage on The Medicines in a research note on Friday, December 14th. They set an “outperform” rating for the company. Finally, Goldman Sachs Group started coverage on The Medicines in a research note on Thursday, December 13th. They set a “neutral” rating and a $25.00 price objective for the company. Three research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $45.00.

TRADEMARK VIOLATION NOTICE: “United Services Automobile Association Purchases 1,020 Shares of The Medicines Company (MDCO)” was first reported by PressOracle and is the sole property of of PressOracle. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://pressoracle.com/news/2019/03/17/united-services-automobile-association-purchases-1020-shares-of-the-medicines-company-mdco.html.

The Medicines Profile

The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.

See Also: Asset Allocation

Want to see what other hedge funds are holding MDCO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Medicines Company (NASDAQ:MDCO).

Institutional Ownership by Quarter for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

Leave a Reply